Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af BBT001 hos raske frivillige (HVS) og hos voksne patienter med atopisk dermatitis (AD)

26. september 2026 opdateret af: Bambusa Therapeutics

En randomiseret, blindet, placebokontrolleret, enkelt- og multiple-asaskende dosisundersøgelse for at evaluere sikkerhed, tolerabilitet, farmakokinetik, immunogenicitet, farmakodynamik og klinisk aktivitet af BBT001 hos HVS og AD-patienter

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

237

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Western Australia
      • Fremantle, Western Australia, Australien, 6160
        • Rekruttering
        • Fremantle Dermatology
      • Perth, Western Australia, Australien, 6009
        • Afsluttet
        • Linear Clinical Research
    • California
      • Irvine, California, Forenede Stater, 92614
        • Rekruttering
        • First OC Dermatology
    • New York
      • New York, New York, Forenede Stater, 10128
        • Rekruttering
        • OptiSkin Medical
      • The Bronx, New York, Forenede Stater, 10455
        • Rekruttering
        • Equity Medical, LLC
      • Christchurch, New Zealand
        • Rekruttering
        • Optimal Clinical Trials Ltd - Christchurch
      • Upper Hutt, New Zealand, 5018
        • Rekruttering
        • Pacific Clinical Research Network (PCRN) Wellington
        • Kontakt:
          • Tim Humphrey
    • Auckland
      • Grafton, Auckland, New Zealand, 1010
        • Rekruttering
        • Optimal Clinical Trials Central Auckland
        • Kontakt:
          • Arna Letica
      • Otahuhu, Auckland, New Zealand, 2025
        • Trukket tilbage
        • Aotearoa Clinical Trials
      • Takapuna, Auckland, New Zealand, 0622
        • Rekruttering
        • Pacific Clinical Research Network (PCRN) - Auckland
        • Kontakt:
          • Paul Hamilton
      • Lodz, Polen, 91-347
        • Rekruttering
        • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
      • Rzeszów, Polen, 35-055
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Warsaw, Polen, 02-507
        • Rekruttering
        • Państwowy Instytut Medyczny MSWiA
      • Wroclaw, Polen, 50-566
        • Rekruttering
        • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 72 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria

  1. Negative pregnancy tests for women of childbearing potential.
  2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
  3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
  4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

  1. Age of 18-65 years.
  2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
  3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

  1. Age of 18-72 years.
  2. Body mass index ≥16 kg/m², weight capped at 125 kg.
  3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
  4. Moderate to severe atopic dermatitis
  5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
  6. Atopic lesions cover ≥10% of body surface area (BSA)
  7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
  5. Abnormal Electrocardiogram (ECG) findings
  6. History of drug/alcohol abuse in the past 2 years.
  7. Donated >500mL blood within 2 months of screening.
  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
  2. Receipt of immunoglobulin or blood products within 30 days.
  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
  4. Chronic pruritus from conditions other than atopic dermatitis.
  5. Acute/treated infections or chronic skin infections.
  6. Current use of sedating antihistamines or corticosteroids.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Eksperimentel: Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

BBT001 will be administered

Eksperimentel: Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo komparator: Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

Placebo will be administered

Placebo komparator: Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

Placebo will be administered

Placebo komparator: Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Placebo komparator: Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo komparator: Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

BBT001 will be administered

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with adverse events following single and multiple administration of BBT001
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in serum blood parameters
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Laboratory assessments include hematology, blood chemistry and coagulation test

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in vital sign measurements following treatment administration.
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Blood pressure and heart rate will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in physical examination following treatment administration.
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Physical examination will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in 12-lead ECG readings
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

12-lead ECG will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Maximum observed concentration of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum PK Tmax will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Area under the curve (AUC)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Area under the curve of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Volume of distribution (Vz)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Volume of distribution of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Total clearance (CL)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Total clearance of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Elimination half-life of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum Anti-Drug Antibodies will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Lisa Li, Bambusa Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. februar 2025

Primær færdiggørelse (Anslået)

28. februar 2027

Studieafslutning (Anslået)

28. februar 2027

Datoer for studieregistrering

Først indsendt

30. januar 2025

Først indsendt, der opfyldte QC-kriterier

30. januar 2025

Først opslået (Faktiske)

5. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner